StrideBio Revenue and Competitors
Estimated Revenue & Valuation
- StrideBio's estimated annual revenue is currently $1.6M per year.
- StrideBio's estimated revenue per employee is $77,500
- StrideBio's total funding is $97.2M.
Employee Data
- StrideBio has 21 Employees.
- StrideBio grew their employee count by -82% last year.
StrideBio's People
Name | Title | Email/Phone |
---|---|---|
1 | VP Strategy & Operations | Reveal Email/Phone |
2 | EVP Finance and Administration | Reveal Email/Phone |
3 | VP Strategy & Operations | Reveal Email/Phone |
4 | VP, Head Finance and Corporate Secretary | Reveal Email/Phone |
5 | VP Regulatory Affairs | Reveal Email/Phone |
6 | VP Patient Engagement & Advocacy | Reveal Email/Phone |
7 | VP Human Resources | Reveal Email/Phone |
8 | VP Strategy & Operations | Reveal Email/Phone |
9 | Chief Development Officer | Reveal Email/Phone |
10 | Founder, Acting Chief Scientific Officer | Reveal Email/Phone |
StrideBio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $11.2M | 72 | -13% | N/A | N/A |
#2 | $5099.8M | 32902 | -4% | N/A | N/A |
#3 | $1.7M | 11 | 0% | N/A | N/A |
#4 | $0.6M | 4 | -56% | N/A | N/A |
#5 | $0.9M | 11 | -39% | N/A | N/A |
#6 | $1.7M | 11 | 10% | N/A | N/A |
#7 | $0.6M | 4 | -33% | N/A | N/A |
#8 | $4.8M | 31 | -6% | N/A | N/A |
#9 | $6.4M | 41 | 3% | N/A | N/A |
#10 | $4.2M | 27 | -18% | N/A | N/A |
What Is StrideBio?
StrideBio is a product-driven, fully integrated gene therapy company focused on creating and developing innovative genetic medicines with life-changing or curative potential for patients with devastating conditions, including monogenic rare disease and beyond. We leverage our proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. Improved characteristics of StrideBioᅢᄁ¬ツᆲ¬トᄁs AAV vectors include evasion of pre-existing neutralizing antibodies, tissue targeting and de-targeting, enhanced potency, and manufacturability at scale. Combined with our gene construct design expertise and in-house manufacturing capabilities, StrideBio is positioned to generate best-in-class genetic medicines that allow more patients to benefit with maximum efficiency. StrideBio is based in a state-of-the-art 24,000-square-foot facility in Research Triangle Park, N.C, which houses our offices, research labs and in-house AAV manufacturing facilities.
keywords:N/A$97.2M
Total Funding
21
Number of Employees
$1.6M
Revenue (est)
-82%
Employee Growth %
N/A
Valuation
N/A
Accelerator
StrideBio News
StrideBio, Inc., a Research Triangle Park, N.C.-based developer of novel engineered adeno-associated virus (AAV) based gene therapies, closed a $81.5m Series B funding round. The round was co-led by Northpond Ventures and Novo Holdings A/S and included new investors Pontifax, Octagon Capital, S ...
RESEARCH TRIANGLE PARK, N.C., March 16, 2021 /PRNewswire/ -- StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round, which raised $81.5 million. The financing was co-led ...
RESEARCH TRIANGLE PARK, N.C., March 16, 2021 /PRNewswire/ -- StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round, which raised $81.5 million. The financing was co-led b ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.3M | 21 | -28% | N/A |
#2 | N/A | 21 | 0% | N/A |
#3 | $3.3M | 21 | 17% | N/A |
#4 | $3.4M | 21 | 0% | N/A |
#5 | $4M | 21 | -25% | N/A |